Janus Henderson Group
BCRX icon

Janus Henderson Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Janus Henderson Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84.9M Buy
8,908,506
+1,504,120
+20% +$11.7M 0.04% 310
2025
Q4 		$57.8M Buy
7,404,386
+7,310,745
+7,807% +$52.9M 0.03% 387
2025
Q3 		$710K Buy
93,641
+14,309
+18% +$119K ﹤0.01% 1841
2025
Q2 		$710K Hold
79,332
– – ﹤0.01% 1780
2025
Q1 		$624K Hold
79,332
– – ﹤0.01% 1845
2024
Q4 		$596K Hold
79,332
– – ﹤0.01% 1952
2024
Q3 		$603K Hold
79,332
– – ﹤0.01% 1943
2024
Q2 		$491K Sell
79,332
-1,053
-1% -$5.81K ﹤0.01% 1997
2024
Q1 		$407K Buy
80,385
+98
+0.1% +$551 ﹤0.01% 2104
2023
Q4 		$481K Sell
80,287
-156
-0.2% -$904 ﹤0.01% 2006
2023
Q3 		$569K Buy
80,443
+7
+0% +$50 ﹤0.01% 1856
2023
Q2 		$566K Sell
80,436
-86
-0.1% -$690 ﹤0.01% 1911
2023
Q1 		$672K Sell
80,522
-1,969,504
-96% -$19M ﹤0.01% 1856
2022
Q4 		$23.5M Buy
2,050,026
+2,014,048
+5,598% +$25.1M 0.02% 538
2022
Q3 		$453K Buy
35,978
+77
+0.2% +$991 ﹤0.01% 1626
2022
Q2 		$380K Sell
35,901
-30
-0.1% -$309 ﹤0.01% 1925
2022
Q1 		$584K Buy
35,931
+9
+0% +$144 ﹤0.01% 1804
2021
Q4 		$498K Buy
35,922
+18,068
+101% +$239K ﹤0.01% 1898
2021
Q3 		$257K Buy
+17,854
New +$282K ﹤0.01% 1964
2020
Q2 		– Sell
-4,877,731
Closed -$9.76M – 1311
2020
Q1 		$9.76M Sell
4,877,731
-4,530,750
-48% -$12.5M 0.01% 820
2019
Q4 		$32.5M Sell
9,408,481
-112,083
-1% -$282K 0.02% 715
2019
Q3 		$27.3M Sell
9,520,564
-75,780
-0.8% -$236K 0.01% 755
2019
Q2 		$36.4M Sell
9,596,344
-2,661,098
-22% -$16M 0.02% 662
2019
Q1 		$99.8M Sell
12,257,442
-45,113
-0.4% -$386K 0.06% 381
2018
Q4 		$99.3M Buy
12,302,555
+52,394
+0.4% +$407K 0.06% 347
2018
Q3 		$93.5M Buy
12,250,161
+1,153,978
+10% +$7.75M 0.05% 417
2018
Q2 		$63.6M Buy
11,096,183
+3,441,498
+45% +$18.9M 0.04% 488
2018
Q1 		$36.5M Buy
7,654,685
+915,419
+14% +$4.7M 0.02% 632
2017
Q4 		$33.1M Buy
6,739,266
+2,204,539
+49% +$10.7M 0.02% 641
2017
Q3 		$23.8M Buy
+4,534,727
New +$23.2M 0.02% 701

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Janus Henderson Group's BCRX Position: Q1 2026 in Review

Janus Henderson Group increased its BioCryst Pharmaceuticals (BCRX) stake by 20% in Q1 2026, buying an estimated $11.7M and bringing the position to 8,908,506 shares worth $84.9M. The position accounts for 0.04% of the portfolio, ranked #310.

Janus Henderson Group first reported a position in BCRX in Q3 2017 and has held it in 30 quarters since. The position peaked at $99.8M in Q1 2019. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Janus Henderson Group held 8,908,506 shares of BioCryst Pharmaceuticals worth $84.9M as of Q1 2026.
  • Janus Henderson Group bought 1,504,120 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $11.7M.
  • BioCryst Pharmaceuticals made up 0.04% of Janus Henderson Group's portfolio in Q1 2026, its #310 holding.
  • Janus Henderson Group first reported a position in BioCryst Pharmaceuticals in Q3 2017 and has held it in 30 quarters since.
  • Janus Henderson Group's BioCryst Pharmaceuticals position peaked at $99.8M in Q1 2019.
  • 302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.